The use of dapagliflozin in comorbid conditions

Chernikova N.A., Ivanova K.O.

1) Russian Medical Academy of Continuous Professional Education, Moscow, Russia; 2) Central Clinical Hospital of Civil Aviation, Moscow, Russia

In modern clinical practice, a trend toward increased multimorbidity is observed among patients with type 2 diabetes. Achieving physiological glycemic control is often insufficient to reduce the risk of cardiovascular complications and progression of renal dysfunction, which are the leading causes of mortality in this group of patients. The search for new approaches and pharmacological interventions targeting multiple pathogenetic components of comorbid conditions is urgent. Sodium-glucose cotransporter-2 inhibitors, particularly dapagliflozin, not only lower blood sugar but also protect cardioretinometabolic function, thereby opening up a wide range of new opportunities in endocrinology, cardiology, and nephrology.

For citations: Chernikova N.A., Ivanova K.O. The use of dapagliflozin in comorbid conditions. Pharmateca. 2026;33(2):39-42. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.2.39-42

Authors’ contribution: All authors made an equivalent contribution to the preparation of the publication.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.

Keywords

About the Authors

Natalia A. Chernikova, Cand. Sci. (Med.), Associate Professor, Department of Endocrinology, Russian Medical Academy of Continuous Professional Education; Head of the Endocrinology Department, Central Clinical Hospital of Civil Aviation, Moscow, Russia; nachendoc@yandex.ru, ORCID: https://orcid.org/0000-0002-0562-8396 (corresponding author)
Ksenia O. Ivanova, Resident, Department of Endocrinology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; ivanovakseniao@mail.ru, ORCID: https://orcid.org/0009-0001-0375-4532

Similar Articles